Abstract |
Considerable evidence is now available to support the pivotal role of the serotonin (5-HT) system is exerting the antidepressant response in humans. Different type of antidepressant treatments enhance 5-HT neurotransmission via different pre- or postsynaptic mechanisms. The time course for the occurrence of these adaptive changes in the brain of laboratory animals is consistent with the delayed onset of the antidepressant response in humans. The drugs effective in obsessive-compulsive disorder (OCD) also enhance 5-HT neurotransmission in brain regions involved in mediating OCD symptoms but with a more prolonged delay, consistently with the larger time necessary to obtain therapeutic effect in OCD than in depression. The elucidation of these mechanisms of action lead to the development of new pharmacologic strategies to potentiate the therapeutic effect of the drugs currently available and the identification of novel targets to accelerate and further improve treatment response in depression and OCD.
|
Authors | P Blier, C de Montigny |
Journal | Biological psychiatry
(Biol Psychiatry)
Vol. 44
Issue 5
Pg. 313-23
(Sep 01 1998)
ISSN: 0006-3223 [Print] United States |
PMID | 9755353
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antidepressive Agents
- Receptors, Serotonin
- Serotonin Uptake Inhibitors
- Serotonin
|
Topics |
- Animals
- Antidepressive Agents
(pharmacology, therapeutic use)
- Depressive Disorder
(drug therapy, physiopathology)
- Humans
- Obsessive-Compulsive Disorder
(drug therapy, physiopathology)
- Receptors, Serotonin
(drug effects, physiology)
- Serotonin
(physiology)
- Selective Serotonin Reuptake Inhibitors
(pharmacology, therapeutic use)
|